144 related articles for article (PubMed ID: 28027810)
1. First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age.
Lindgren LM; Tingskov PN; Justesen AH; Nedergaard BS; Olsen KJ; Andreasen LV; Kromann I; Sørensen C; Dietrich J; Thierry-Carstensen B
Vaccine; 2017 Jan; 35(4):596-604. PubMed ID: 28027810
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
Verdijk P; Rots NY; van Oijen MG; Oberste MS; Boog CJ; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2013 Nov; 31(47):5531-6. PubMed ID: 24063976
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age.
Bravo LC; Carlos JC; Gatchalian SR; Montellano MEB; Tabora CFCB; Thierry-Carstensen B; Tingskov PN; Sørensen C; Wachmann H; Bandyopadhyay AS; Nielsen PI; Kusk MV
Vaccine; 2020 Jan; 38(3):530-538. PubMed ID: 31703934
[TBL] [Abstract][Full Text] [Related]
5. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China.
Li R; Li CG; Li Y; Liu Y; Zhao H; Chen X; Kuriyakose S; Van Der Meeren O; Hardt K; Hezareh M; Roy-Ghanta S
Vaccine; 2016 Mar; 34(12):1436-43. PubMed ID: 26873055
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
[TBL] [Abstract][Full Text] [Related]
7. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
[TBL] [Abstract][Full Text] [Related]
8. Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV.
Gajdos V; Vidor E; Richard P; Tran C; Sadorge C
Vaccine; 2015 Jul; 33(32):3988-96. PubMed ID: 26087294
[TBL] [Abstract][Full Text] [Related]
9. [Immunogenicity and safety of a booster dose of inactivated polio vaccine].
Li XM; Zhang ZJ; Wang HH; Liu F; Zhang LW; Chu P; Xu Y; Zhang HR; Li J; Liu DL; Lu L
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):905-9. PubMed ID: 24378129
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells.
Haastrup E; Thierry-Carstensen B; Jensen AM; Stellfeld M; Heilmann C
Vaccine; 2004 Feb; 22(8):958-62. PubMed ID: 15161072
[TBL] [Abstract][Full Text] [Related]
11. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3.5, 5 and 16 months of age.
Pietrzyk JJ; Wysocki J; Pejcz J; Galaj A; Majda-Stanislawska E; Käyhty H; Thierry-Carstensen B; Jensen AM
Vaccine; 2008 Sep; 26(41):5296-303. PubMed ID: 18675870
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial.
Snider CJ; Zaman K; Estivariz CF; Yunus M; Weldon WC; Wannemuehler KA; Oberste MS; Pallansch MA; Wassilak SG; Bari TIA; Anand A
Lancet; 2019 Jun; 393(10191):2624-2634. PubMed ID: 31104832
[TBL] [Abstract][Full Text] [Related]
14. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4-6 years.
Black S; Friedland LR; Schuind A; Howe B;
Vaccine; 2006 Aug; 24(35-36):6163-71. PubMed ID: 16759769
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart.
Embree J; Law B; Voloshen T; Tomovici A
Clin Vaccine Immunol; 2015 Mar; 22(3):282-90. PubMed ID: 25540274
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
[TBL] [Abstract][Full Text] [Related]
19. Long-term immunogenicity assessment of a DTaP-IPV//PRP-T vaccine given at 2, 4, 6 and 18-19 months of age, and immunogenicity and safety of a DTaP-IPV vaccine given as a booster dose at 4 to 6 years of age in Thai children.
Pancharoen C; Chotpitayasunondh T; Chuenkitmongkol S; Ortiz E
Southeast Asian J Trop Med Public Health; 2012 May; 43(3):687-98. PubMed ID: 23077849
[TBL] [Abstract][Full Text] [Related]
20. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba.
Resik S; Tejeda A; Fonseca M; Alemañi N; Diaz M; Martinez Y; Garcia G; Okayasu H; Burton A; Bakker WA; Verdijk P; Sutter RW
Vaccine; 2014 Sep; 32(42):5399-404. PubMed ID: 25131734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
